Print

Nymox Pharmaceutical (NYMX) NX-1207 Prostate Cancer Trial Receives Second Positive Interim Safety Review From Independent Data Monitoring Committee  
10/9/2012 9:06:33 AM

HASBROUCK HEIGHTS, N.J., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that the Independent Data Monitoring Committee for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) has reported a second positive analysis of safety data from the clinical trial. The Independent Data Monitoring Committee assessed patients to date who have received high dose NX-1207 for treatment of their localized prostate cancer. The Independent Data Monitoring Committee is an arm's length independent body mandated to conduct periodic interim safety reviews at pre-determined stages during the study. The Committee has the authority to recommend changes to the study or to halt the study in the event of unacceptable drug toxicity. The Committee's interim safety analysis found no evidence of such toxicity and accordingly the study is continuing.
//-->